Cargando…

Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities

Rationale: Osteoporosis is a severe bone disorder that is a threat to our aging population. Excessive osteoclast formation and bone resorption lead to changes in trabecular bone volume and architecture, leaving the bones vulnerable to fracture. Therapeutic approaches of inhibiting osteoclastogenesis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yuhao, Wang, Chao, Wang, Gang, Sun, Youqiang, Deng, Zhangrong, Chen, Leilei, Chen, Kai, Tickner, Jennifer, Kenny, Jacob, Song, Dezhi, Zhang, Qingwen, Wang, Haibin, Chen, Zhenqiu, Zhou, Chi, He, Wei, Xu, Jiake
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643439/ https://www.ncbi.nlm.nih.gov/pubmed/31367247 http://dx.doi.org/10.7150/thno.35414

Ejemplares similares

Dracorhodin perchlorate inhibits osteoclastogenesis through repressing RANKL‐stimulated NFATc1 activity
por: Liu, Yuhao, et al.
Publicado: (2020)

Asiatic Acid Inhibits OVX-Induced Osteoporosis and Osteoclastogenesis Via Regulating RANKL-Mediated NF-κb and Nfatc1 Signaling Pathways
por: Hong, Guoju, et al.
Publicado: (2020)

Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL‐induced osteoclastogenesis
por: Jin, Haiming, et al.
Publicado: (2019)

Maackiain dampens osteoclastogenesis via attenuating RANKL‐stimulated NF‐κB signalling pathway and NFATc1 activity
por: Liu, Yuhao, et al.
Publicado: (2020)

Cytochalasin Z11 inhibits RANKL-induced osteoclastogenesis via suppressing NFATc1 activation
por: Wang, Lu, et al.
Publicado: (2019)

Evodiamine inhibits RANKL‐induced osteoclastogenesis and prevents ovariectomy‐induced bone loss in mice
por: Jin, Haiming, et al.
Publicado: (2018)

Madecassoside inhibits estrogen deficiency‐induced osteoporosis by suppressing RANKL‐induced osteoclastogenesis
por: Wang, Qingqing, et al.
Publicado: (2018)

Betulinic Acid Protects From Bone Loss in Ovariectomized Mice and Suppresses RANKL-Associated Osteoclastogenesis by Inhibiting the MAPK and NFATc1 Pathways
por: Wei, Jiyong, et al.
Publicado: (2020)

Loureirin B downregulates osteoclast differentiation of bone marrow macrophages by targeting the MAPK signaling pathway
por: Zhang, Jiahao, et al.
Publicado: (2022)

12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis via Inhibiting ROS Level and Regulating RANKL-Mediated NFATc1 Activation
por: He, Qi, et al.
Publicado: (2022)

Adseverin mediates RANKL-induced osteoclastogenesis by regulating NFATc1
por: Song, Min-Kyoung, et al.
Publicado: (2015)

MCU Inhibitor Ruthenium Red Alleviates the Osteoclastogenesis and Ovariectomized Osteoporosis via Suppressing RANKL-Induced ROS Production and NFATc1 Activation through P38 MAPK Signaling Pathway
por: Wang, Yuxin, et al.
Publicado: (2022)

Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF-κB, Calcium, and NFATc1 Pathways
por: Wang, Gang, et al.
Publicado: (2022)

Inhibitory Effects of Rhaponticin on Osteoclast Formation and Resorption by Targeting RANKL-Induced NFATc1 and ROS Activity
por: He, Jianbo, et al.
Publicado: (2021)

Asperpyrone A attenuates RANKL‐induced osteoclast formation through inhibiting NFATc1, Ca(2+) signalling and oxidative stress
por: Chen, Xi, et al.
Publicado: (2019)

Pseurotin A Inhibits Osteoclastogenesis and Prevents Ovariectomized-Induced Bone Loss by Suppressing Reactive Oxygen Species
por: Chen, Kai, et al.
Publicado: (2019)

Matrine prevents bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclastogenesis
por: Chen, Xiao, et al.
Publicado: (2017)

Fumitremorgin C Attenuates Osteoclast Formation and Function via Suppressing RANKL-Induced Signaling Pathways
por: Yuan, Yu, et al.
Publicado: (2020)

Tetrandrine Prevents Bone Loss in Ovariectomized Mice by Inhibiting RANKL-Induced Osteoclastogenesis
por: Zhong, Zeyuan, et al.
Publicado: (2020)

Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways
por: Yang, Xue, et al.
Publicado: (2021)

Peiminine Suppresses RANKL-Induced Osteoclastogenesis by Inhibiting the NFATc1, ERK, and NF-κB Signaling Pathways
por: Zhu, Mengbo, et al.
Publicado: (2021)

Nitazoxanide, an Antiprotozoal Drug, Reduces Bone Loss in Ovariectomized Mice by Inhibition of RANKL-Induced Osteoclastogenesis
por: Li, Chang-hong, et al.
Publicado: (2021)

C-phycocyanin attenuates RANKL-induced osteoclastogenesis and bone resorption in vitro through inhibiting ROS levels, NFATc1 and NF-κB activation
por: AlQranei, Mohammed S., et al.
Publicado: (2020)

PRMT1 mediates RANKL-induced osteoclastogenesis and contributes to bone loss in ovariectomized mice
por: Choi, Joo-Hee, et al.
Publicado: (2018)

TGFβ1 Regulates Human RANKL-Induced Osteoclastogenesis via Suppression of NFATc1 Expression
por: Tokunaga, Tadahiro, et al.
Publicado: (2020)

Corrigendum: Nitazoxanide, an antiprotozoal drug, reduces bone loss in ovariectomized mice by inhibition of RANKL-induced osteoclastogenesis
por: Li, Chang-hong, et al.
Publicado: (2023)

Anemonin Attenuates RANKL-Induced Osteoclastogenesis and Ameliorates LPS-Induced Inflammatory Bone Loss in Mice via Modulation of NFATc1
por: Hou, Huanhuan, et al.
Publicado: (2020)

The Molecular Mechanisms Study of Engeletin Suppresses RANKL-Induced Osteoclastogenesis and Inhibits Ovariectomized Murine Model Bone Loss
por: Feng, Mingzhe, et al.
Publicado: (2023)

The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat
por: Ashtar, Mohannad, et al.
Publicado: (2020)

Angelica sinensis extract inhibits RANKL-mediated osteoclastogenesis by down-regulated the expression of NFATc1 in mouse bone marrow cells
por: Kong, Lingbo, et al.
Publicado: (2014)

Water extract of Cnidii Rhizoma suppresses RANKL-induced osteoclastogenesis in RAW 264.7 cell by inhibiting NFATc1/c-Fos signaling and prevents ovariectomized bone loss in SD-rat
por: Lee, Ka-Yeon, et al.
Publicado: (2019)

STIM1 controls calcineurin/Akt/mTOR/NFATC2-mediated osteoclastogenesis induced by RANKL/M-CSF
por: Huang, Yanjiao, et al.
Publicado: (2020)

Tyloxapol inhibits RANKL-stimulated osteoclastogenesis and ovariectomized-induced bone loss by restraining NF-κB and MAPK activation
por: Guo, Wen, et al.
Publicado: (2021)

Agelasine D Suppresses RANKL-Induced Osteoclastogenesis via Down-Regulation of c-Fos, NFATc1 and NF-κB
por: Kang, Moo Rim, et al.
Publicado: (2014)

Inhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant RANKL
por: Jang, Yuria, et al.
Publicado: (2021)

Green tea (Camellia sinensis) aqueous extract alleviates postmenopausal osteoporosis in ovariectomized rats and prevents RANKL-induced osteoclastogenesis in vitro
por: Wu, Xin, et al.
Publicado: (2018)

Bu-Shen-Ning-Xin decoction suppresses osteoclastogenesis by modulating RANKL/OPG imbalance in the CD4(+) T lymphocytes of ovariectomized mice
por: Zhang, Jia-Li, et al.
Publicado: (2018)

Urolithin B suppresses osteoclastogenesis via inhibiting RANKL‐induced signalling pathways and attenuating ROS activities
por: Qu, Zechao, et al.
Publicado: (2022)

Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT
por: Hong, Guoju, et al.
Publicado: (2017)

Umbelliferone Prevents Lipopolysaccharide-Induced Bone Loss and Suppresses RANKL-Induced Osteoclastogenesis by Attenuating Akt-c-Fos-NFATc1 Signaling
por: Kwak, Sung Chul, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e6uqri0jmatbr8i1vnjmqdn793